Lisdexamfetamine treatment for cocaine dependence

赖右苯丙胺治疗可卡因依赖

• 批准号: 7758094
• 负责人: David Vance Herin
• 金额: $ 24.9万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2012-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7758094
• 关键词: Abstinence; Adoption; Adult; Agonist; Amphetamine Abuse; Amphetamines; Applications Grants; Award; Clinical; Clinical Trials; Cocaine; Cocaine Dependence; Collaborations; Communities; Data; Development; Dextroamphetamine; Disease; Doctor of Philosophy; Drug Delivery Systems; Drug Formulations; FDA approved; Faculty; Functional Imaging; Funding Agency; Future; Health Sciences; Human Genetics; Impulsivity; Individual; Kinetics; Laboratory Study; Literature; Measures; Minnesota; Modeling; Movement; National Institute of Drug Abuse; Pathway interactions; Patients; Pharmaceutical Preparations; Pharmacological Treatment; Phase; Placebos; Population; Positioning Attribute; Preparation; Probability; Prodrugs; Property; Psychiatry; Public Health; Request for Proposals; Research; Resistance; Risk; Secure; Societies; Statistical Methods; Substance abuse problem; TNFRSF5 gene; Technology; Texas; Training; Universities; Urine; Work; analog; career; cocaine use; craving; experience; innovation; responsible research conduct; skills; treatment strategy

This proposal requests support for the ROO phase of the K99/R00 Pathway to Independence Award enabling David Herin, Ph.D, to begin his independent career investigating pharmacological treatments for substance abuse. The first (K99) phase ofthis award has been conducted at the University of Texas Health Science Center at Houston (UTHSC) under Drs. John Grabowski and Joy Schmitz. In this phase, Dr. Herin completed training in clinicai trials metholodology, advanced statistical methods, the responsible conduct of research, as well as u-aining in professional skills. Additionally, Dr. Herin obtained experience in implementation of clinical trials in multiple studies at the UTHSC P50 medication development center, and developed collaborations with departmental faculty. This clinical training has enabled Dr. Herin lo secure a tenure-track faculty position in the Department of Psychiatry at the University of Minnesota. As Dr. Herin launches his independent career, ROO support will enable him to conduct a clinical trial investigating the ability of lisdexamfetamine to treat cocaine dependence. During this ROO period, Dr. Herin will also develop collaborations with his University of Minnesota colleagues in fields such as functional imaging, impulsivity, genetics, and human laboratory studies, enabling submission of future interdisciplinary grant applications to funding agencies. In all, the K99 and ROO awards permit Dr. Herin to begin his independent career and make significant scientific contributions to the field of substance abuse research.

该提案要求支持K99/R 00独立之路奖的ROO阶段，使大卫赫林博士能够开始他的独立职业生涯，研究药物滥用的药物治疗。该奖项的第一阶段（K99）在德克萨斯大学休斯顿健康科学中心（UTHSC）由John Grabowski和Joy Schmitz博士进行。在这一阶段，Herin博士完成了临床试验方法学、高级统计方法、负责任的研究行为以及专业技能的培训。此外，Herin博士在UTHSC P50药物开发中心的多项研究中获得了实施临床试验的经验，并与部门教师开展了合作。这种临床培训使Herin lo博士在明尼苏达大学精神病学系获得了终身教职。随着Herin博士开始他的独立职业生涯，ROO的支持将使他能够进行一项临床试验，调查lisdexamfetamine治疗可卡因依赖的能力。在ROO期间，Herin博士还将与明尼苏达大学的同事在功能成像、 冲动，遗传学和人类实验室研究，使未来的跨学科资助申请提交给资助机构。总之，K99和ROO奖允许Herin博士开始他的独立职业生涯，并为药物滥用研究领域做出重大的科学贡献。